• Quizartinib (AC220): FLT3 Assay Interpretation Guide

  2026-08-07

  Quizartinib (AC220) is a selective FLT3 inhibitor for acute myeloid leukemia research. This guide moves beyond potency claims to show how target engagement, signaling state, resistance biology, and cross-disease model selection should shape FLT3 experiments.

• Tivozanib (AV-951): Advanced Protocols for VEGFR Inhibition

  2026-08-07

  Tivozanib (AV-951) stands out as a next-generation VEGFR inhibitor, enabling refined in vitro and in vivo studies of tumor angiogenesis and therapeutic resistance. This article details actionable experimental workflows, troubleshooting strategies, and insights from cutting-edge research—empowering oncology laboratories to leverage Tivozanib with precision.

• Magneto-Piezoelectric Nanoparticle Scaffolds Activate JAK2-S

  2026-08-06

  This study introduces multifunctional scaffolds enhanced with magneto-piezoelectric nanoparticles that disrupt bacterial biofilms and stimulate oxidative phosphorylation in Icam1+ macrophages. By activating the JAK2-STAT3 pathway, these scaffolds address both infection control and bone regeneration in infectious bone defects, opening new avenues for immune-modulatory biomaterials.

• Exo1: Precision Membrane Trafficking Inhibition for Exocytos

  2026-08-06

  Exo1 (methyl 2-(4-fluorobenzamido)benzoate) empowers researchers with acute, mechanistically unique inhibition of the exocytic pathway, enabling advanced dissection of Golgi-ER membrane dynamics. Its distinct action profile makes it invaluable for studying extracellular vesicle biology and overcoming the limitations of classic inhibitors.

• Tofacitinib (CP-690550): Advancing Immune Modulation Assays

  2026-08-05

  Tofacitinib (CP-690550) stands out as a powerful tool for immune modulation research, enabling precise inhibition of interleukin signaling and restoration of mitochondrial function in inflammatory models. This article distills the latest mechanistic breakthroughs and provides actionable protocols and troubleshooting guidance to accelerate immune cell and cytokine signaling studies.

• Scenario-Driven Solutions with ARCA Cy5 EGFP mRNA (5-moUTP)

  2026-08-05

  This article addresses key challenges in mRNA delivery and assay reproducibility, guiding researchers through real-world scenarios where ARCA Cy5 EGFP mRNA (5-moUTP) (SKU R1009) offers validated, data-driven solutions. The piece explores optimization, data interpretation, and vendor reliability, emphasizing the scientific and workflow advantages of this 5-methoxyuridine modified mRNA.

• Salvianolic acid B: Applied Workflows for Pulmonary Fibrosis

  2026-08-04

  Salvianolic acid B (Dan Shen Suan B) is redefining fibrosis research as a high-purity, evidence-backed inhibitor of LH2-mediated collagen cross-linking. Unlock advanced experimental workflows and troubleshooting strategies that empower researchers to target extracellular matrix remodeling with precision.

• Magneto-Piezoelectric Scaffolds Activate JAK2-STAT3 for Bone

  2026-08-04

  Wu et al. developed multifunctional scaffolds enhanced with magneto-piezoelectric nanoparticles to simultaneously disrupt biofilms and activate oxidative phosphorylation in Icam1+ macrophages, thereby promoting infectious bone defect regeneration. This work demonstrates a dual approach that bridges infection control and immune-metabolic modulation, providing new directions for regenerative biomaterials research.

• RCN2 Drives Metastasis and Cisplatin Resistance in ESCC via

  2026-08-03

  This study uncovers Reticulocalbin 2 (RCN2) as a key driver of metastasis and cisplatin resistance in esophageal squamous cell carcinoma (ESCC), acting through UBR5-mediated degradation of PPP2CA and activation of the PI3K-AKT pathway. These findings highlight new molecular targets and potential strategies for overcoming treatment resistance in ESCC.

• Precision RNA Synthesis for Translational Oncology: Lessons

  2026-08-03

  Harnessing mechanistic insight from LINC02613’s role in oral squamous cell carcinoma (OSCC) metastasis, this article provides strategic guidance for translational researchers pursuing RNA-based interventions. By dissecting cutting-edge findings and situating them alongside practical workflow advances with the HyperScribe™ T7 High Yield RNA Synthesis Kit, we outline a blueprint for accelerating the development and deployment of functional RNA tools—bridging discovery, validation, and therapeutic innovation.

• Liproxstatin-1: Precision Ferroptosis Inhibitor for Research

  2026-08-02

  Liproxstatin-1 is a potent ferroptosis inhibitor with proven nanomolar efficacy, enabling robust investigation of iron-dependent cell death and lipid peroxidation. This guide translates bench research into optimized protocols, troubleshooting strategies, and comparative insights for advancing ferroptosis research in cancer, neurodegeneration, and renal models.

• Pentoxifylline Dampens Monocyte Hyperinflammation in Preterm

  2026-08-01

  This study demonstrates that pentoxifylline (PTX) significantly downregulates LPS-induced hyperinflammatory responses in monocytes from preterm infants in vitro. The findings provide mechanistic insights into PTX's age-specific effects on cytokine production and monocyte activation, supporting its further evaluation as an adjunctive therapy in neonatal sepsis.

• Liproxstatin-1: Applied Ferroptosis Inhibitor Workflows & Ti

  2026-07-31

  Liproxstatin-1 is a standout ferroptosis inhibitor for cell and animal models, offering nanomolar precision in blocking lipid peroxidation and rescuing GPX4-deficient systems. Explore advanced workflows, troubleshooting strategies, and cross-domain experimental enhancements informed by the latest research.

• AG-490 (JAK2/EGFR inhibitor): Scenario-Driven Solutions for

  2026-07-31

  This article addresses common laboratory challenges in cell viability and immunopathology assays, demonstrating how AG-490 (JAK2/EGFR inhibitor, SKU A4139) improves reproducibility and data quality. Through scenario-driven Q&A, we bridge real-world assay pitfalls with evidence-based applications, referencing the latest literature and validated protocols.

• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor-S

  2026-07-30

  This study introduces a robust patient-derived gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal cell subpopulations. By recapitulating the tumor microenvironment more accurately than previous models, the system enables in-depth investigation of tumor biology, drug response variability, and resistance mechanisms, offering new opportunities for personalized therapy optimization.

541 records 8/37 page Previous Next First page 上5页 678910 下5页 Last page